Please use this identifier to cite or link to this item:
|Title:||The inodilator levosimendan in repetitive doses in the treatment of advanced heart failure.|
|Citation:||Eur Heart J Suppl.2017 Mar;(19)Suppl C:C8-C14|
|Abstract:||Inotropes may be an appropriate response for some patients with advanced heart failure who remain highly symptomatic despite optimization of evidence-based therapy. These patients need to be supported waiting for a heart transplant or ventricular assist device, or may be candidates for inotropy as an intervention in its own right to maintain a patient in the best achievable circumstances. Objectives in such a situation include relieving symptoms, improving quality of life and reducing unplanned hospitalizations and the costs associated with such admissions. Levosimendan, a calcium sensitizer and potassium channel opener with inotrope and vasodilator actions, has emerged as a potentially valuable addition to the armamentarium in this context, used in repeated or intermittent cycles of therapy. Detailed proposals and guidance are offered for the identification of candidate patients with good prospects of a beneficial response to levosimendan, and for the safe and effective implementation of a course of therapy.|
|Appears in Collections:||Hospitales > H. U. 12 de Octubre > Artículos|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.